No Data
Inter-trade etc [Stocks with notable appeal viewed from volume change]
Closing prices and volume compared to the previous day *<6190> PXB 3646447100 *<5616> Rain, Wind, Sun 84912672300 *<3747> Intertrade 441694784100 *<4406> Shin Nihon Rika 212221919600 *<7162> Astomax 2595499600 *<4772> Stream M 131142906000 *<7578> Nichiryouku 1508124900 *<4331> T & G Needs 87479221600 *<41
Emerging markets stock digest: UNITED is sharply up, HOUSEI hits the daily limit.
Marked rebound. The invention related to 'Marker Peptides for the Measurement of ALT1 and ALT2' has been patented in japan, which has been well received.
PXB --- significant rebound, regarding the Japanese patent approval for "marker peptides for measuring ALT1 and ALT2".
Significant rebound. The invention related to 'marker peptides for the measurement of ALT1 and ALT2' has been granted a patent in japan, which has been well received. This patent successfully differentiates between human ALT and mouse ALT in chimeric mice, such as the PXB mouse and disease model mice, using LC-MS/MS (a combination of liquid chromatography and tandem mass spectrometry), achieving what was difficult with conventional methods.
Phoenix Bio --- In the second quarter, although there was a decrease in revenue, the demand for PXB mice is increasing as they transition from the hepatitis field to the bio-pharmaceutical field.
Phoenix Bio <6190> announced its consolidated financial results for the second quarter of the fiscal year ending March 2025 (April-September 24). The revenue decreased by 10.6% year-on-year to 0.788 billion yen, operating loss was 0.098 billion yen (compared to a loss of 0.005 billion yen in the same period last year), ordinary loss was 0.123 billion yen (compared to a profit of 0.045 billion yen), and the interim net loss attributable to the parent company's shareholders was 0.124 billion yen (compared to a profit of 0.027 billion yen). The demand for PXB mice is transitioning from the hepatitis area to the biopharmaceutical field, with nucleic acid.
Starting lineup, Rental Trucks and others.
<142A> Jingib stem inc downward revision, current fiscal year operating profit forecast 0.008 billion yen ← 0.24 billion yen <145A> Acquired shares of System M's, a company that handles development of Ellyusbee system (web system/ OA/FA system) etc., and made it a subsidiary <149A> Sync Inc downward revision, current fiscal year operating profit forecast 0.073 billion yen ← 0.171 billion yen <157A> Established a subsidiary of G Monster <195A> Rice curry performance financial estimates revision, current fiscal year operating profit forecast 0.125 billion yen ← 0.32 billion yen electric motor A
PhoenixBio: Confirmation letter
No Data
No Data